Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis
- 19 December 2006
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 103 (51), 19546-19551
- https://doi.org/10.1073/pnas.0609411103
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal, progressive paralysis arising from the premature death of motor neurons. An inherited form is caused by a dominant mutation in the ubiquitously expressed superoxide dismutase (SOD1). SOD1 mutant expression within motor neurons is a determinant of onset and early disease, and mutant accumulation within microglia accelerates disease progression. Muscle also is a likely primary source for toxicity, because retraction of motor axons from synaptic connections to muscle is among the earliest presymptomatic events. To test involvement of muscle in ALS, viral delivery of transcription-mediated siRNA is shown to suppress mutant SOD1 accumulation within muscle alone but to be insufficient to maintain grip strength, whereas delivery to both motor neurons and muscle is sufficient. Use of a deletable mutant gene to diminish mutant SOD1 from muscle did not affect onset or survival. Finally, follistatin expression encoded by adeno-associated virus chronically inhibited myostatin and produced sustained increases in muscle mass, myofiber number, and fiber diameter, but these increases did not affect survival. Thus, SOD1-mutant-mediated damage within muscles is not a significant contributor to non-cell-autonomous pathogenesis in ALS, and enhancing muscle mass and strength provides no benefit in slowing disease onset or progression.This publication has 51 references indexed in Scilit:
- Intramuscular viral delivery of paraplegin rescues peripheral axonopathy in a model of hereditary spastic paraplegiaJCI Insight, 2005
- Myostatin, a negative regulator of muscle mass: implications for muscle degenerative diseasesCurrent Opinion in Pharmacology, 2005
- Synergy of insulin‐like growth factor‐1 and exercise in amyotrophic lateral sclerosisAnnals of Neurology, 2005
- Virus‐delivered small RNA silencing sustains strength in amyotrophic lateral sclerosisAnnals of Neurology, 2005
- UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALSAnnual Review of Neuroscience, 2004
- Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosisAnnals of Neurology, 2003
- Target-Derived Cardiotrophin-1 and Insulin-like Growth Factor-I Promote Neurite Growth and Survival of Developing Oculomotor NeuronsMolecular and Cellular Neuroscience, 2002
- A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattleNature Genetics, 1997
- Activity‐Sensitive Signaling by Muscle‐Derived Insulin‐like Growth Factors in the Developing and Regenerating Neuromuscular SystemAnnals of the New York Academy of Sciences, 1993
- Effect of exercise on the motor unitMuscle & Nerve, 1986